Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Change in Cash (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Change in Cash data on record, last reported at $71.6 million in Q3 2025.

  • For Q3 2025, Change in Cash fell 59.37% year-over-year to $71.6 million; the TTM value through Sep 2025 reached -$244.6 million, down 185.0%, while the annual FY2024 figure was $262.9 million, 2639.5% up from the prior year.
  • Change in Cash reached $71.6 million in Q3 2025 per ZBIO's latest filing, up from -$152.5 million in the prior quarter.
  • Across five years, Change in Cash topped out at $176.1 million in Q3 2024 and bottomed at -$152.5 million in Q2 2025.
  • Average Change in Cash over 3 years is $5.4 million, with a median of -$17.6 million recorded in 2023.
  • The widest YoY moves for Change in Cash: up 59.37% in 2025, down 525.71% in 2025.
  • A 3-year view of Change in Cash shows it stood at -$15.5 million in 2023, then plummeted by 160.74% to -$40.3 million in 2024, then surged by 277.59% to $71.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $71.6 million in Q3 2025, -$152.5 million in Q2 2025, and -$123.3 million in Q1 2025.